{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:58:46Z","timestamp":1793249926842,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004629"],"award-info":[{"award-number":["INV-004629"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jvacx.2021.100113","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T01:21:47Z","timestamp":1632100907000},"page":"100113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing"],"prefix":"10.1016","volume":"9","author":[{"given":"Jacob H.","family":"Gillis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-2217","authenticated-orcid":false,"given":"Keely N.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilkumar","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2060-1220","authenticated-orcid":false,"given":"Mallikarjuna","family":"Panchakshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9706-5585","authenticated-orcid":false,"given":"Rose T.","family":"Byrne-Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy L.","family":"Rowlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-2956","authenticated-orcid":false,"given":"Erica","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2021.100113_b0005","unstructured":"World Health Organization. Global Measles and Rubella Strategic Plan: 2012-2020. 2012."},{"key":"10.1016\/j.jvacx.2021.100113_b0010","unstructured":"Measles Signs and Symptoms | CDC n.d. https:\/\/www.cdc.gov\/measles\/symptoms\/signs-symptoms.html (accessed November 11, 2020)."},{"key":"10.1016\/j.jvacx.2021.100113_b0015","unstructured":"Measles | WHO n.d. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/measles (accessed July 1, 2021)."},{"key":"10.1016\/j.jvacx.2021.100113_b0020","unstructured":"Measles Complications | CDC n.d. https:\/\/www.cdc.gov\/measles\/symptoms\/complications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmeasles%2Fabout%2Fcomplications.html (accessed November 11, 2020)."},{"key":"10.1016\/j.jvacx.2021.100113_b0025","unstructured":"Rubella - Symptoms and causes - Mayo Clinic n.d. https:\/\/www.mayoclinic.org\/diseases-conditions\/rubella\/symptoms-causes\/syc-20377310 (accessed November 12, 2020)."},{"key":"10.1016\/j.jvacx.2021.100113_b0030","unstructured":"INTRODUCING RUBELLA VACCINE INTO NATIONAL IMMUNIZATION PROGRAMMES A STEP-BY-STEP GUIDE. 2015."},{"key":"10.1016\/j.jvacx.2021.100113_b0035","unstructured":"Congenital Rubella Syndrome Congenital Rubella Syndrome Vaccine-Preventable Diseases. 2018."},{"issue":"suppl_2","key":"10.1016\/j.jvacx.2021.100113_b0040","doi-asserted-by":"crossref","first-page":"S571","DOI":"10.1093\/infdis\/jir472","article-title":"Elimination of rubella and congenital rubella syndrome in the Americas","volume":"204","author":"Castillo-Sol\u00f3rzano","year":"2011","journal-title":"J Infect Dis"},{"issue":"52","key":"10.1016\/j.jvacx.2021.100113_b0045","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1098\/rsif.2010.0086","article-title":"Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population","volume":"7","author":"van Boven","year":"2010","journal-title":"J R Soc Interf"},{"issue":"2","key":"10.1016\/j.jvacx.2021.100113_b0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/S0950268800051785","article-title":"Outbreak of measles in a teenage school population: the need to immunize susceptible adolescents","volume":"113","author":"Morse","year":"1994","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jvacx.2021.100113_b0055","doi-asserted-by":"crossref","unstructured":"Ramsay ME. Measles: the legacy of low vaccine coverage n.d. https:\/\/doi.org\/10.1136\/archdischild-2013-304292.","DOI":"10.1136\/archdischild-2013-304292"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100113_b0060","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00006454-198307000-00005","article-title":"Clinical efficacy of rubella vaccine","volume":"2","author":"Greaves","year":"1983","journal-title":"Pediatric Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100113_b0065","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ije\/24.4.842","article-title":"Assessing the efficacy of a mixed vaccination strategy against rubella in S\u00e3o Paulo, Brazil","volume":"24","author":"Massad","year":"1995","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jvacx.2021.100113_b0070","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/infdis\/jir155","article-title":"Progress toward control of rubella and prevention of congenital rubella syndrome - Worldwide, 2009","volume":"204","author":"Reef","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2021.100113_b0075","doi-asserted-by":"crossref","unstructured":"Hayman B, Pagliusi S. Emerging vaccine manufacturers are innovating for the next decade. Vaccine: X 2020;5:100066. https:\/\/doi.org\/10.1016\/j.jvacx.2020.100066.","DOI":"10.1016\/j.jvacx.2020.100066"},{"key":"10.1016\/j.jvacx.2021.100113_b0080","doi-asserted-by":"crossref","unstructured":"Patel MK, Goodson JL, Alexander JP, Kretsinger K, Sodha S v., Steulet C, et al. Progress Toward Regional Measles Elimination \u2014 Worldwide, 2000\u20132019. MMWR Morbidity and Mortality Weekly Report 2020;69:1700\u20135. https:\/\/doi.org\/10.15585\/mmwr.mm6945a6.","DOI":"10.15585\/mmwr.mm6945a6"},{"issue":"9","key":"10.1016\/j.jvacx.2021.100113_b0085","doi-asserted-by":"crossref","first-page":"e24135","DOI":"10.1371\/journal.pone.0024135","article-title":"Rapid titration of measles and other viruses: Optimization with determination of replication cycle length","volume":"6","author":"Grigorov","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jvacx.2021.100113_b0090","unstructured":"WHO Technical Report Series, No. 840, Annex 3. 1994."},{"issue":"3","key":"10.1016\/j.jvacx.2021.100113_b0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13337-012-0105-0","article-title":"A colorimetric-based accurate method for the determination of enterovirus 71 titer","volume":"23","author":"Pourianfar","year":"2012","journal-title":"Indian J Virol"},{"issue":"2","key":"10.1016\/j.jvacx.2021.100113_b0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-0934(01)00316-0","article-title":"Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays","volume":"96","author":"LaBarre","year":"2001","journal-title":"J Virol Meth"},{"issue":"1","key":"10.1016\/j.jvacx.2021.100113_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0099-3","article-title":"A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines","volume":"4","author":"Byrne-Nash","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jvacx.2021.100113_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-018-0080-6","article-title":"VaxArray potency assay for rapid assessment of \u201cpandemic\u201d influenza vaccines","volume":"3","author":"Byrne-Nash","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"10","key":"10.1016\/j.jvacx.2021.100113_b0115","doi-asserted-by":"crossref","first-page":"e109616","DOI":"10.1371\/journal.pone.0109616","article-title":"Titer on Chip: New Analytical Tool for Influenza Vaccine Potency Determination","volume":"9","author":"Kuck","year":"2014","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.jvacx.2021.100113_b0120","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.vaccine.2017.02.028","article-title":"VaxArray assessment of influenza split vaccine potency and stability","volume":"35","author":"Kuck","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2021.100113_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1037\/h0063767","article-title":"Review of the Method of \u201cRight and Wrong Cases\u201d ('Constant Stimuli\u2019) without Gauss\u2019s Formula","volume":"6","author":"Spearman","year":"1909","journal-title":"Psychol Bull"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100113_b0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn-Schmiedebergs Archiv F\u00fcr Experimentelle Pathologie Und Pharmakologie"},{"key":"10.1016\/j.jvacx.2021.100113_b0135","series-title":"Field\u2019s Virology","author":"Knipe","year":"2013"},{"issue":"9","key":"10.1016\/j.jvacx.2021.100113_b0140","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1128\/jcm.30.9.2323-2329.1992","article-title":"Cellular and Humoral Immune Responses to Rubella Virus Structural Proteins E1, E2, and C","volume":"30","author":"Chaye","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jvacx.2021.100113_b0145","unstructured":"FDA, CBER. Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live. n.d."},{"key":"10.1016\/j.jvacx.2021.100113_b0150","unstructured":"ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) Guideline on Validation of Analytical Procedures: Methodology developed to complement the Parent Guideline 2005."},{"issue":"5","key":"10.1016\/j.jvacx.2021.100113_b0155","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4161\/hv.4.5.5863","article-title":"Stabilization of measles virus for vaccine formulation","volume":"4","author":"Kissmann","year":"2008","journal-title":"Human Vaccines"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136221000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136221000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:04:33Z","timestamp":1762913073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136221000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"alternative-id":["S2590136221000309"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2021.100113","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.05.433809","asserted-by":"object"}]},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2021.100113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100113"}}